Tadocizumab Biosimilar - Research Grade

Human

ITGA2B_ITGB3ï؟½

5mg/ml

Fab - G1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P08514;P05106

Blue ice

The platelet integrin alphaIIb/beta3 (GPIIb/IIIa) mediates fibrinogen binding and platelet aggregation, a central process in thrombosis research. This reagent is a non-therapeutic, unconjugated analog of tadocizumab, supplied as a recombinant Fab fragment directed against the alphaIIb/beta3 complex, for research use only. It is manufactured to in vivo standards in a low-endotoxin format and produced in scalable milligram to gram quantities for high-throughput laboratories. Applications include platelet-aggregation functional assays, in vitro integrin-binding screens, and in vivo thrombosis models. Its purity and dependable supply support reproducible work in demanding, high-throughput settings. Consistent quality across lots makes it a practical choice for laboratories running sustained study programs.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks